Tumor Lysis in Neonates and Infants

  • Carolina Witchmichen Penteado Schmidt


Tumor lysis syndrome is a massive lysis of malignant cells due to quick proliferation, and it is characterized by hyperuricemia, hyperkalemia, and hyperphosphatemia. Hyperphosphatemia may lead to hypocalcemia. Tumor lysis syndrome usually develops after the start of chemotherapy and may lead to acute renal failure and death, due to renal tubular precipitation of uric acid and other complications. The risk factors for development of tumor lysis syndrome are malignancies with large growth fraction (i.e. B-cell and T-cell lymphomas/leukemias), large tumor bulk, use of cytolytic chemotherapy, pre-existing renal insufficiency, kidney involvement, ureteral or bladder obstruction by the tumor, and metabolic abnormalities [95].


  1. 95.
    Emory University School of Medicine. Department of Pediatrics: Tumor lysis syndrome; 2006.
  2. 4.
    Taketomo C, Hodding J, Kraus D. Pediatric & neonatal dosage handbook. 21st ed. Hudson: Lexicomp; 2014.Google Scholar
  3. 69.
    McNutt DM, Holdsworth MT, Wong C, Hanrahan JD, Winter SS. Rasburicase for the management of tumor lysis syndrome in neonates. Ann Pharmacother. 2006;40(7–8):1445–50.CrossRefGoogle Scholar
  4. 70.
    Tragiannidis A, Pana ZD, Papageorgiou T, et al. Transient myeloproliferative disorder in a newborn with Down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: a case report. J Med Case Reports. 2011;5:407.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Carolina Witchmichen Penteado Schmidt
    • 1
  1. 1.CuritibaBrazil

Personalised recommendations